公开(公告)号：US20120072124A1

公开(公告)日：2012-03-22

申请号：US13207282

申请日：2011-08-10

申请人： Jerald P. Radich ,  Hongyue Dai ,  Mao Mao ,  Janell M. Schelter ,  Peter S. Linsley

发明人： Jerald P. Radich ,  Hongyue Dai ,  Mao Mao ,  Janell M. Schelter ,  Peter S. Linsley

IPC分类号： G06F19/20 ,  G01N33/50

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y02A90/26

摘要： The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins.

摘要翻译： 本发明提供了与慢性骨髓性白血病（CML）进展相关的分子标记，以及用于基于这些分子标记物的测量来监测患者中CML进展的方法和计算机系统。 本发明还提供CML靶基因，以及通过调节这些CML靶基因和/或其编码蛋白的表达或活性来治疗CML患者的方法和组合物。 本发明还提供了与CML患者中对伊马替尼甲磺酸盐（Gleevec TM）治疗有关的基因，以及基于这些基因和/或其编码蛋白质的测量来确定CML患者对甲磺酸伊马替尼治疗的反应性的方法和组合物 。 本发明还提供了通过调节这些基因和/或其编码的蛋白质的表达或活性来增强Gleevec TM的作用的方法和组合物。

公开(公告)号：US20090239214A1

公开(公告)日：2009-09-24

申请号：US11658605

申请日：2005-08-01

申请人： Hongyue Dai ,  Yudong He ,  Mao Mao ,  Bernard Fine ,  Laura J. van't Veer ,  Marc J. van de Vijver

发明人： Hongyue Dai ,  Yudong He ,  Mao Mao ,  Bernard Fine ,  Laura J. van't Veer ,  Marc J. van de Vijver

IPC分类号： C12Q1/68 ,  G06F19/00

CPC分类号： G01N33/57415 ,  B01J2219/00378 ,  B01J2219/00385 ,  B01J2219/00527 ,  B01J2219/00576 ,  B01J2219/00585 ,  B01J2219/00596 ,  B01J2219/00605 ,  B01J2219/0061 ,  B01J2219/00612 ,  B01J2219/00626 ,  B01J2219/00641 ,  B01J2219/00675 ,  B01J2219/00677 ,  B01J2219/00693 ,  B01J2219/00711 ,  B01J2219/00722 ,  B82Y30/00 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  G16B25/00 ,  G16B40/00

摘要： The present invention relates to sets of genetic markers whose expression is correlated with prognosis of breast cancer in individuals having breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate individuals having a good prognosis, e.g., no reoccurrence or metastasis within five years of initial diagnosis, and individuals having a poor prognosis, e.g., reoccurrence or metastasis within five years of initial diagnosis. The invention relates to methods of prognosis using these markers. The invention also relates to microarrays containing probes to these markers, and to kits containing ready-to-use microarrays and computer software for data analysis using the prognostic and statistical methods disclosed herein.

摘要翻译： 本发明涉及具有乳腺癌个体的表达与乳腺癌预后相关的遗传标记组。 具体地，本发明提供了一组标志物，其表达模式可用于区分具有良好预后的个体，例如在初始诊断的五年内不再发生或转移，以及在五年内具有差的预后，例如再发生或转移的个体 的初步诊断。 本发明涉及使用这些标记物的预后方法。 本发明还涉及含有这些标记物的探针的微阵列，以及包含即用型微阵列的试剂盒和用于使用本文公开的预后和统计学方法进行数据分析的计算机软件。

公开(公告)号：US20060292623A1

公开(公告)日：2006-12-28

申请号：US11510798

申请日：2006-08-25

申请人： Peter Linsley ,  Mao Mao ,  Hongyue Dai ,  Yudong He ,  Jerald Radich

发明人： Peter Linsley ,  Mao Mao ,  Hongyue Dai ,  Yudong He ,  Jerald Radich

IPC分类号： C12Q1/68 ,  G06F19/00

CPC分类号： G01N33/57426 ,  C12Q1/6837 ,  C12Q1/6886 ,  C12Q2600/158 ,  G16B25/00

摘要： The present invention relates to genetic markers whose expression is correlated with progression of CML. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate chronic phase individuals from those in blast crisis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

公开(公告)号：US20110301048A1

公开(公告)日：2011-12-08

申请号：US12953314

申请日：2010-11-23

申请人： HongYue Dai ,  Yudong He ,  Peter S. Linsley ,  Mao Mao ,  Christopher J. Roberts ,  Laura Johanna Van't Veer ,  Marc J. Van de Vijver ,  Rene Bernards ,  A.A. M. Hart

发明人： HongYue Dai ,  Yudong He ,  Peter S. Linsley ,  Mao Mao ,  Christopher J. Roberts ,  Laura Johanna Van't Veer ,  Marc J. Van de Vijver ,  Rene Bernards ,  A.A. M. Hart

IPC分类号： C40B30/02 ,  C40B40/06 ,  C40B30/04

CPC分类号： C12Q1/6886 ,  C12Q2600/158 ,  G01N33/57415 ,  G06F19/00 ,  G16B25/00 ,  G16B40/00 ,  Y02A90/22 ,  Y02A90/26

摘要： The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

摘要翻译： 本发明涉及其表达与乳腺癌相关的遗传标记。 具体地，本发明提供了一组标志物，其表达模式可用于区分与乳腺癌相关的临床病症，例如雌激素受体ESR1和BRCA1和散发性肿瘤的存在或不存在，并提供关于肿瘤可能性的信息 初步诊断五年内远处转移。 本发明涉及使用这些标记来区分这些条件的方法。 本发明还涉及包含即用型微阵列的试剂盒和用于使用本文公开的统计学方法进行数据分析的计算机软件。

公开(公告)号：US20070154931A1

公开(公告)日：2007-07-05

申请号：US11640517

申请日：2006-12-14

申请人： Jerald Radich ,  Hongyue Dai ,  Mao Mao ,  Janell Schelter ,  Peter Linsley

发明人： Jerald Radich ,  Hongyue Dai ,  Mao Mao ,  Janell Schelter ,  Peter Linsley

IPC分类号： C12Q1/68 ,  G06F19/00

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y02A90/26

摘要： The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins.

摘要翻译： 本发明提供了与慢性骨髓性白血病（CML）进展相关的分子标记，以及用于基于这些分子标记物的测量来监测患者中CML进展的方法和计算机系统。 本发明还提供CML靶基因，以及通过调节这些CML靶基因和/或其编码蛋白的表达或活性来治疗CML患者的方法和组合物。 本发明还提供了与CML患者中对甲磺酸伊马替尼（Gleevec TM）的抗药性相关的基因，以及基于这些基因和/或它们的测量来确定CML患者对甲磺酸伊马替尼治疗的反应性的方法和组合物 编码的蛋白质。 本发明还提供了通过调节这些基因和/或其编码的蛋白质的表达或活性来增强Gleevec TM的作用的方法和组合物。

公开(公告)号：US08014957B2

公开(公告)日：2011-09-06

申请号：US11640517

申请日：2006-12-14

申请人： Jerald P. Radich ,  Hongyue Dai ,  Mao Mao ,  Janell M. Schelter ,  Peter S. Linsley

发明人： Jerald P. Radich ,  Hongyue Dai ,  Mao Mao ,  Janell M. Schelter ,  Peter S. Linsley

IPC分类号： G01N33/48

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y02A90/26

摘要： The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins.

摘要翻译： 本发明提供了与慢性骨髓性白血病（CML）进展相关的分子标记，以及用于基于这些分子标记物的测量来监测患者中CML进展的方法和计算机系统。 本发明还提供CML靶基因，以及通过调节这些CML靶基因和/或其编码蛋白的表达或活性来治疗CML患者的方法和组合物。 本发明还提供了与CML患者中对伊马替尼甲磺酸盐（Gleevec TM）治疗有关的基因，以及基于这些基因和/或其编码蛋白质的测量来确定CML患者对甲磺酸伊马替尼治疗的反应性的方法和组合物 。 本发明还提供了通过调节这些基因和/或其编码的蛋白质的表达或活性来增强Gleevec TM的作用的方法和组合物。

公开(公告)号：US07863001B2

公开(公告)日：2011-01-04

申请号：US12214878

申请日：2008-06-23

申请人： HongYue Dai ,  Yudong He ,  Peter S. Linsley ,  Mao Mao ,  Christopher J. Roberts ,  Laura Johanna Van't Veer ,  Marc J. Van de Vijver ,  Rene Bernards ,  Augustinus A. M. Hart

发明人： HongYue Dai ,  Yudong He ,  Peter S. Linsley ,  Mao Mao ,  Christopher J. Roberts ,  Laura Johanna Van't Veer ,  Marc J. Van de Vijver ,  Rene Bernards ,  Augustinus A. M. Hart

IPC分类号： C12Q1/68 ,  G01N33/48 ,  C07H21/00

CPC分类号： C12Q1/6886 ,  C12Q2600/158 ,  G01N33/57415 ,  G06F19/00 ,  G06F19/20 ,  G06F19/24 ,  Y02A90/22 ,  Y02A90/26

摘要： The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

摘要翻译： 本发明涉及其表达与乳腺癌相关的遗传标记。 具体地，本发明提供了一组标志物，其表达模式可用于区分与乳腺癌相关的临床病症，例如雌激素受体ESR1和BRCA1和散发性肿瘤的存在或不存在，并提供关于肿瘤可能性的信息 初步诊断五年内远处转移。 本发明涉及使用这些标记来区分这些条件的方法。 本发明还涉及包含即用型微阵列的试剂盒和用于使用本文公开的统计学方法进行数据分析的计算机软件。

公开(公告)号：US07514209B2

公开(公告)日：2009-04-07

申请号：US10172118

申请日：2002-06-14

申请人： HongYue Dai ,  Yudong He ,  Peter S. Linsley ,  Mao Mao ,  Christopher J. Roberts ,  Laura Johanna Van't Veer ,  Marc J. Van de Vijver ,  Rene Bernards ,  Augustinus A. M. Hart

发明人： HongYue Dai ,  Yudong He ,  Peter S. Linsley ,  Mao Mao ,  Christopher J. Roberts ,  Laura Johanna Van't Veer ,  Marc J. Van de Vijver ,  Rene Bernards ,  Augustinus A. M. Hart

IPC分类号： C12Q1/68 ,  G01N33/48 ,  C07H21/00

CPC分类号： C12Q1/6886 ,  C12Q2600/158 ,  G01N33/57415 ,  G06F19/00 ,  G06F19/20 ,  G06F19/24 ,  Y02A90/22 ,  Y02A90/26

摘要： The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.

公开(公告)号：US20090004645A1

公开(公告)日：2009-01-01

申请号：US11578216

申请日：2005-04-12

申请人： Mao Mao ,  Aimee Jackson ,  Peter S. Linskey ,  Hongyue Dai

发明人： Mao Mao ,  Aimee Jackson ,  Peter S. Linskey ,  Hongyue Dai

IPC分类号： C12Q1/68

CPC分类号： C12N15/1072 ,  C12N15/111 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2320/12

摘要： In one aspect, the present invention provides methods for determining whether a gene mediates the response of a living cell to an agent. In another aspect, the present invention provides methods to identify a mammalian subject responsive to a KSP inhibitor.

摘要翻译： 一方面，本发明提供了确定基因介导活细胞对药剂的反应的方法。 在另一方面，本发明提供了鉴定对KSP抑制剂的哺乳动物受试者的方法。

公开(公告)号：US20050181385A1

公开(公告)日：2005-08-18

申请号：US10947637

申请日：2004-09-22

申请人： Peter Linsley ,  Mao Mao ,  Annette Kim ,  Stephen Friend ,  Steven Bartz ,  Michele Cleary

发明人： Peter Linsley ,  Mao Mao ,  Annette Kim ,  Stephen Friend ,  Steven Bartz ,  Michele Cleary

IPC分类号： C07H21/02 ,  C12N15/11 ,  C12N15/85 ,  C12Q1/68

CPC分类号： C12N15/111 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2320/12

摘要： The invention provides a method for identifying one or more genes in a cell of a cell type which interact with, e.g., modulate the effect of, an agent, e.g., a drug. For example, an identified gene may confer resistance or sensitivity to a drug, i.e., reduces or enhances the effect of the drug. The invention also provides STK6 and TPX2 as a gene that exhibits synthetic lethal interactions with KSP encoding a kinesin-like motor protein, and methods and compositions for treatment of diseases, e.g., cancers, by modulating the expression of STK6 or TPX2 gene and/or the activity of STK6 or TPX2 gene product. The invention also provides genes involved in cellular response to DNA damage, and their therapeutic uses.

摘要翻译： 本发明提供了一种用于鉴定与例如药物的作用相互作用的细胞类型的细胞中的一种或多种基因的方法。 例如，鉴定的基因可赋予药物抗药性或敏感性，即降低或增强药物的作用。 本发明还提供STK6和TPX2作为与编码驱动蛋白样运动蛋白的KSP呈现合成的致死相互作用的基因，以及通过调节STK6或TPX2基因的表达和/或治疗疾病例如癌症的方法和组合物 STK6或TPX2基因产物的活性。 本发明还提供涉及对DNA损伤的细胞反应及其治疗用途的基因。